Journey Medical Corporation to Present at the Emerging Growth Conference
Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on FDA-approved dermatological treatments, announced its upcoming presentation at the Emerging Growth Conference. Claude Maraoui, Co-Founder, President and CEO, will deliver a corporate overview on August 20, 2025, at 12:35 p.m. ET.
The presentation will be conducted virtually through video webcasts. Investors can access the live event by registering at emerginggrowth.com/conference, and an archived version will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
Journey Medical Corporation (NASDAQ:DERM), azienda farmaceutica in fase commerciale specializzata in trattamenti dermatologici approvati dalla FDA, ha annunciato la sua prossima presentazione all'Emerging Growth Conference. Claude Maraoui, cofondatore, presidente e CEO, terrà una panoramica aziendale il 20 agosto 2025 alle 12:35 ET.
La presentazione sarà trasmessa virtualmente tramite webcast video. Gli investitori possono seguire l'evento in diretta registrandosi su emerginggrowth.com/conference; una registrazione sarà poi disponibile su EmergingGrowth.com e sul canale YouTube di Emerging Growth.
Journey Medical Corporation (NASDAQ:DERM), una compañía farmacéutica en etapa comercial centrada en tratamientos dermatológicos aprobados por la FDA, anunció su próxima presentación en la Emerging Growth Conference. Claude Maraoui, cofundador, presidente y CEO, ofrecerá una presentación corporativa el 20 de agosto de 2025 a las 12:35 p.m. ET.
La presentación se realizará de forma virtual mediante webcasts de video. Los inversores pueden acceder al evento en vivo registrándose en emerginggrowth.com/conference; una versión archivada estará disponible en EmergingGrowth.com y en el canal de YouTube de Emerging Growth.
Journey Medical Corporation (NASDAQ:DERM), FDA 승인 피부과 치료제를 전문으로 하는 상업 단계 제약회사, 가 Emerging Growth Conference에서 발표할 예정이라고 발표했습니다. 공동창업자이자 사장 겸 CEO인 Claude Maraoui가 2025년 8월 20일 오후 12시 35분(동부표준시)에 회사 개요를 발표합니다.
발표는 비디오 웨비캐스트를 통해 온라인으로 진행됩니다. 투자자는 emerginggrowth.com/conference에서 등록하여 실시간으로 시청할 수 있으며, 발표 녹화본은 EmergingGrowth.com과 Emerging Growth 유튜브 채널에 아카이브로 제공됩니다.
Journey Medical Corporation (NASDAQ:DERM), une entreprise pharmaceutique en phase commerciale spécialisée dans les traitements dermatologiques approuvés par la FDA, a annoncé sa prochaine intervention à l'Emerging Growth Conference. Claude Maraoui, cofondateur, président et PDG, présentera un aperçu de l'entreprise le 20 août 2025 à 12h35 ET.
La présentation se déroulera virtuellement via des webcasts vidéo. Les investisseurs peuvent accéder à l'événement en direct en s'inscrivant sur emerginggrowth.com/conference ; une version archivée sera disponible sur EmergingGrowth.com et sur la chaîne YouTube d'Emerging Growth.
Journey Medical Corporation (NASDAQ:DERM), ein Pharmaunternehmen in der kommerziellen Phase mit Schwerpunkt auf FDA-zugelassenen dermatologischen Behandlungen, kündigte seine bevorstehende Präsentation auf der Emerging Growth Conference an. Claude Maraoui, Mitbegründer, Präsident und CEO, wird am 20. August 2025 um 12:35 Uhr ET einen Unternehmensüberblick geben.
Die Präsentation wird virtuell per Video-Webcast übertragen. Investoren können die Live-Veranstaltung durch Registrierung unter emerginggrowth.com/conference verfolgen; eine Archivversion wird auf EmergingGrowth.com und dem Emerging Growth YouTube-Kanal verfügbar sein.
- None.
- None.
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.
For more information or to register for the conference, please visit: https://emerginggrowth.com/conference/.
If attendees are unable to join the live event, an archived webcast will also be made available on EmergingGrowth.com and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When is Journey Medical (NASDAQ:DERM) presenting at the Emerging Growth Conference?
Who will be presenting for Journey Medical at the Emerging Growth Conference?
How can investors access Journey Medical's Emerging Growth Conference presentation?
What is Journey Medical's (DERM) main business focus?
